| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/OXFORDJOURNALS.BMB.A072464 |
| P953 | full work available at URL | http://academic.oup.com/bmb/article-pdf/47/1/87/7285041/47-1-87.pdf |
| http://bmb.oxfordjournals.org/cgi/content/abstract/47/1/87 | ||
| P698 | PubMed publication ID | 1863851 |
| P2093 | author name string | W. J. Gullick | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 87-98 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | British Medical Bulletin | Q15750363 |
| P1476 | title | Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers | |
| P478 | volume | 47 |
| Q26775711 | A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer |
| Q48218073 | A Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation |
| Q37068772 | A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer |
| Q71058161 | A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor |
| Q36079584 | A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines |
| Q36642158 | A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer |
| Q42831336 | A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo |
| Q36081826 | A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations |
| Q40828610 | A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells |
| Q53457015 | Alterations in transforming growth factor-alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. |
| Q28217100 | An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells |
| Q71680646 | Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor |
| Q39697849 | Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma |
| Q34841821 | Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure |
| Q49164511 | Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC. |
| Q24791935 | Barrett's oesophagus and adenocarcinoma |
| Q92487810 | CD317 Activates EGFR by Regulating Its Association with Lipid Rafts |
| Q41020850 | Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line |
| Q35017851 | Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells |
| Q22254063 | Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors |
| Q40815002 | Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. |
| Q31882118 | Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. |
| Q71235333 | Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue |
| Q36617757 | Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells |
| Q33801908 | Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. |
| Q72688309 | Conformation of the transmembrane domain of the epidermal growth factor receptor |
| Q34721253 | Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. |
| Q42493129 | Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development |
| Q41911341 | Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor |
| Q34149071 | Convergence between Wnt-β-catenin and EGFR signaling in cancer |
| Q34079555 | DNA-carrier proteins for targeted gene delivery |
| Q34187436 | Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy |
| Q41349050 | Direct cell killing by suicide genes |
| Q38112122 | Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer |
| Q38915711 | Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets |
| Q34572101 | Does phosphorylation of cofilin affect the progression of human bladder cancer? |
| Q48679475 | Dogs are man's best friend: in sickness and in health. |
| Q77391462 | Down-regulation of epidermal growth factor receptor-signaling pathway by binding of GRP78/BiP to the receptor under glucose-starved stress conditions |
| Q52552851 | Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. |
| Q34130669 | Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis. |
| Q40665432 | EGF receptor expression, regulation, and function in breast cancer |
| Q35804783 | EGFR activation and ultraviolet light-induced skin carcinogenesis |
| Q40378678 | EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization |
| Q35900858 | EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine |
| Q74033216 | EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q37885731 | Emerging therapeutic targets in schwannomas and other merlin-deficient tumors |
| Q28378298 | Endocrine treatment in prostate cancer |
| Q41159083 | Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway |
| Q24532786 | Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors |
| Q35978088 | Epidermal growth factor and transforming growth factor alpha characteristics of human oral carcinoma cell lines |
| Q55483610 | Epidermal growth factor induces glucose transport in primary cell cultures derived from human astrocytic glioma biopsies |
| Q34988074 | Epidermal growth factor receptor and bladder cancer |
| Q37101643 | Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis |
| Q42497044 | Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts |
| Q35761590 | Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma |
| Q72597179 | Epidermal growth factor receptor expression in squamous cell lung carcinomas: an immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material |
| Q34105339 | Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance |
| Q32065139 | Epidermal growth factor receptor induced apoptosis: potentiation by inhibition of Ras signaling |
| Q36090650 | Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells |
| Q41128220 | Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities |
| Q33315034 | Epidermal growth factor receptor structural alterations in gastric cancer |
| Q42440737 | Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer |
| Q28365466 | Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase |
| Q41216128 | Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities |
| Q36490427 | ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. |
| Q35783042 | Estrogen receptor pathways in lung cancer |
| Q31045910 | Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis |
| Q48244729 | Expression of EGF-receptor related protein (ERRP) decreases in gastric mucosa during aging and carcinogenesis |
| Q28285266 | Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types |
| Q37553428 | Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions. |
| Q34334826 | Genes, chromatin, and breast cancer: an epigenetic tale |
| Q43810780 | Growth Factors, Growth Factor Receptors and Neoplasia |
| Q35271481 | Growth factors in the gastrointestinal tract |
| Q24318727 | Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells |
| Q43968093 | Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. |
| Q24595150 | Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera |
| Q41385521 | Immunohistochemical examination of 11 cell lines derived from human head and neck squamous cell carcinomas, their recurrences or metastases |
| Q35975727 | Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction |
| Q45933143 | In silico QSAR studies of anilinoquinolines as EGFR inhibitors. |
| Q36081599 | In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody |
| Q36270213 | In vivo assessment of the regulation of transforming growth factor alpha, epidermal growth factor (EGF), and EGF receptor in the human endometrium by medroxyprogesterone acetate |
| Q48154674 | In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. |
| Q34651534 | Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors |
| Q42440321 | Inhibition of NF-κB Sensitizes A431 Cells to Epidermal Growth Factor-induced Apoptosis, whereas Its Activation by Ectopic Expression of RelA Confers Resistance |
| Q35261397 | Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis |
| Q41125972 | Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies |
| Q47965858 | Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis |
| Q24649294 | Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin |
| Q74623160 | Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) |
| Q36135626 | Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections |
| Q37488529 | Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells |
| Q74453793 | Localization of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study |
| Q36002945 | Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cells |
| Q54492847 | Mechanisms of EGF receptor regulation in breast cancer cells. |
| Q35588724 | Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? |
| Q31151322 | Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. |
| Q46362794 | Model of vascular desmoplastic multispecies tumor growth |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q34982933 | Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances |
| Q39268499 | Molecular modeling study bioactive natural product of khellin analogues as a novel potential pharmacophore of EGFR inhibitors |
| Q77839075 | Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy |
| Q78825116 | Monoclonal antibody (MAB) in patients with advanced cancer |
| Q41338172 | Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway |
| Q36556065 | Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. |
| Q39754858 | New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres |
| Q37243228 | Novel human antibody therapeutics: the age of the Umabs |
| Q35790783 | Novel targeted agents in the treatment of lung cancer |
| Q41713799 | Novel therapeutic strategies to selectively kill cancer cells. |
| Q43221529 | Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus |
| Q81578551 | Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study |
| Q46375104 | Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. |
| Q36134525 | Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer |
| Q35748395 | Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity |
| Q92282100 | Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail signaling pathway |
| Q33812878 | Pro-invasive stimuli and the interacting protein Hsp70 favour the route of alpha-enolase to the cell surface |
| Q73468817 | Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status |
| Q55209158 | Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. |
| Q41399872 | Protein binding modulates inhibition of the epidermal growth factor receptor kinase and DNA synthesis by tyrphostins |
| Q35107736 | RETRACTED: 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity |
| Q30481746 | RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility |
| Q44944450 | Radioimmunolocalization of head and neck tumors with a new monoclonal antibody against the EGF receptor. Preliminary results |
| Q34571988 | Radiotherapy and cellular signalling |
| Q71680641 | Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer |
| Q41013193 | Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway |
| Q41994915 | Regulation of receptor tyrosine kinase ligand processing |
| Q33944394 | Regulation of the ErbB3 binding protein Ebp1 by protein kinase C. |
| Q34571869 | Repopulation of tumour cells between cycles of chemotherapy: a neglected factor |
| Q42439142 | Requirement for epidermal growth factor receptor tyrosine kinase and for 12-lipoxygenase activity in the expression of 12-lipoxygenase in human epidermoid carcinoma cells. |
| Q35285611 | Role of epidermal growth factor and transforming growth factor alpha in the developing stomach |
| Q84461270 | Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors |
| Q73733584 | Screening for inducers of kinase degradation |
| Q40931569 | Selective GRB2 SH2 inhibitors as anti-Ras therapy |
| Q44526164 | Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells |
| Q40015717 | Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling |
| Q74493684 | Solid-phase, single nucleotide primer extension of DNA/RNA hybrids by reverse transcriptases |
| Q36821859 | Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines |
| Q41270902 | Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibody |
| Q27678732 | Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains |
| Q54375700 | Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. |
| Q42820654 | Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors |
| Q35803133 | Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications |
| Q44198312 | Synergistic inhibitory effects of transplatin and beta-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor |
| Q39687568 | Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase |
| Q46480750 | Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives |
| Q52317261 | TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. |
| Q39999288 | Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha |
| Q73798465 | Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin |
| Q36213631 | Taxifolin suppresses UV-induced skin carcinogenesis by targeting EGFR and PI3K. |
| Q41687874 | The autocrine loop of TGF-alpha/EGFR and brain tumors |
| Q35975667 | The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. |
| Q34602545 | The significance of immunohistochemistry in the diagnosis and therapy of neoplasms |
| Q40541045 | The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. |
| Q36402296 | Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer |
| Q37406217 | Use of liposomes as drug delivery vehicles for treatment of melanoma. |
| Q80221748 | [Epidermal growth factor receptor inhibitors side effects] |
| Q39651377 | α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation |
Search more.